Prévisions

Aucune donnée d'analyste n'est disponible pour cette entreprise.

Actualités Accéder au fil d'actualités

Polyrizon concludes contracts with all five study centers for NASARIX study

Polyrizon has finalized agreements with the fourth and fifth clinical centers, thereby contracting all five sites for the first human study of NASARIX (PL-14). The prospective, multicenter, randomized, single‑blind, two‑arm study will treat up to 120 patients with seasonal allergic rhinitis in a 1:1 ratio with either NASARIX or an isotonic saline spray. The primary endpoint is the difference in the average daily reflective total nasal symptom score over the first 14 days of treatment; safety and several secondary efficacy endpoints, as well as contextual data on pollen counts and weather, will also be collected. » Plus sur de.investing.com
Polyrizon: European publication of patent application for nasal drug delivery

The European Patent Office has completed the technical preparations to publish Polyrizon’s patent application EP 4751737 for the mucoadhesive "Trap & Target" platform. The technology aims to increase residence time in the nasal cavity and improve drug uptake of intranasally administered medicines. The application now enters the European examination procedure; if granted, it could provide protection in several European markets. » Plus sur de.investing.com
Polyrizon extends exclusivity period for takeover talks with Arrow Aviation

Polyrizon has extended the exclusivity period and the initial negotiation phase for the planned acquisition of a 51 percent stake in Arrow Aviation until June 30, 2026. All other terms of the existing letter of intent remain unchanged. The extension builds on the non-binding letter of intent announced in February 2026. » Plus sur de.investing.com

Données financières de l'entreprise

Au dernier trimestre, POLYRIZON LTD Aktie a réalisé un chiffre d'affaires de 0,00€ et un bénéfice net de −2,69M€

(EUR)	déc. 2025	YoY
Chiffre d'affaires	0,00	-
Bénéfice brut	−130,40k	-
Bénéfice net	−2,69M	-
EBITDA	−3,08M	-

Données fondamentales

Indicateur	Valeur
Capitalisation boursière	+10,29M€
Nombre d'actions	1,12M
Plus haut/bas sur 52 semaines	+15,62€ - +2,47€
Dividendes	Non
Bêta	-1,45
Ratio P/E	−3,06
Ratio PEG	−0,01
Ratio P/B	+0,82
Ratio P/S	0,00

Profil de l'entreprise

Polyrizon Ltd. ist ein Biotech-Unternehmen, das sich in Israel mit der Entwicklung von medizintechnischen Hydrogelen in Form von Nasensprays beschäftigt. Die Nasensprays des Unternehmens bilden eine Barriere gegen den Kontakt von Viren und Allergenen mit dem Nasenepithelgewebe. Es entwickelt PL-14, einen nasalen Allergie-Blocker, PL-15 für COVID-19 und PL-16 für Influenza. Das Unternehmen wurde 2005 gegründet und hat seinen Hauptsitz in Ra'anana, Israel.